MedMira (MedMira) EPS (Basic) : $-0.00 (TTM As of Jan. 2024)

View and export this data going back to . Start your Free Trial

What is MedMira EPS (Basic)?

MedMira's basic earnings per share (Basic EPS) for the three months ended in Jan. 2024 was $-0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jan. 2024 was $-0.00.

MedMira's EPS (Diluted) for the three months ended in Jan. 2024 was $-0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 was $-0.00.

MedMira's EPS without NRI for the three months ended in Jan. 2024 was $-0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jan. 2024 was -0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

MedMira EPS (Basic) Historical Data

The historical data trend for MedMira's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira EPS (Basic) Chart

MedMira Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

EPS (Basic)

Get a 7-Day Free Trial

MedMira Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
EPS (Basic)	Get a 7-Day Free Trial															-	-	-	-	-

MedMira EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

MedMira's Basic EPS for the fiscal year that ended in Jul. 2023 is calculated as

Basic EPS (A: Jul. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-2.026	-	0)	/	697.446
	=	-0.00

MedMira's Basic EPS for the quarter that ended in Jan. 2024 is calculated as

Basic EPS (Q: Jan. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.44	-	0)	/	698.088
	=	-0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00

MedMira (OTCPK:MMIRF) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

MedMira EPS (Basic) Related Terms

Thank you for viewing the detailed overview of MedMira's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

MedMira (MedMira) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

47M:Germany MIR:Canada

Address

155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3

Website

https://www.medmira.com

MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.